Directly acting oral anticoagulants for the prevention of stroke in atrial fibrillation in England and Wales: cost-effectiveness model and value of information analysis
Objectives. Determine the optimal, licensed, first-line anticoagulant for prevention of
ischemic stroke in patients with non-valvular atrial fibrillation (AF) in England and Wales …
ischemic stroke in patients with non-valvular atrial fibrillation (AF) in England and Wales …
[HTML][HTML] Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting
Y Zheng, SV Sorensen, AK Gonschior, H Noack… - Clinical …, 2014 - Elsevier
Purpose Three new oral anticoagulants (NOACs) have recently become available in the
United Kingdom as an alternative to warfarin in the prevention of stroke and systemic …
United Kingdom as an alternative to warfarin in the prevention of stroke and systemic …
[HTML][HTML] Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation
Abstract Background Apixaban (5 mg BID), dabigatran (available as 150 mg and 110 mg
BID in Europe), and rivaroxaban (20 mg once daily) are 3 novel oral anticoagulants …
BID in Europe), and rivaroxaban (20 mg once daily) are 3 novel oral anticoagulants …
Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia
Objective To determine the cost-effectiveness of apixaban versus warfarin in patients with
atrial fibrillation (AF) with a moderate to severe risk of stroke, from an Australian government …
atrial fibrillation (AF) with a moderate to severe risk of stroke, from an Australian government …
[HTML][HTML] Cost-Effectiveness of apixaban compared with edoxaban for stroke prevention in nonvalvular atrial fibrillation
GYH Lip, T Lanitis, T Kongnakorn, H Phatak… - Clinical Therapeutics, 2015 - Elsevier
Purpose The purpose of this analysis was to assess the cost-effectiveness of apixaban 5 mg
BID versus high-and low-dose edoxaban (60 mg and 30 mg once daily) as intended starting …
BID versus high-and low-dose edoxaban (60 mg and 30 mg once daily) as intended starting …
[图书][B] Efficacy and cost-effectiveness of new oral anticoagulants compared to warfarin for the prevention of stroke in patients with atrial fibrillation
Background: Warfarin has been used as the only oral anticoagulant for over 50 years in
patients with atrial fibrillation. Recently new oral anticoagulants like dabigatran, rivaroxaban …
patients with atrial fibrillation. Recently new oral anticoagulants like dabigatran, rivaroxaban …
Clinical and cost effectiveness of apixaban compared to aspirin in patients with atrial fibrillation: an Australian perspective
Objective To determine the clinical and cost effectiveness of apixaban compared to aspirin
in the prevention of thromboembolic events for patients with atrial fibrillation for whom …
in the prevention of thromboembolic events for patients with atrial fibrillation for whom …
Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world'atrial fibrillation population: a modelling analysis …
A Banerjee, DA Lane… - Thrombosis and …, 2012 - thieme-connect.com
The concept of net clinical benefit has been used to quantify the balance between risk of
ischaemic stroke (IS) and risk of intracranial haemorrhage (ICH) with the use oral …
ischaemic stroke (IS) and risk of intracranial haemorrhage (ICH) with the use oral …
Stroke and systemic embolism prevention in patients with atrial fibrillation in Belgium: comparative cost effectiveness of new oral anticoagulants and warfarin
T Kongnakorn, T Lanitis, L Annemans, V Thijs… - Clinical drug …, 2015 - Springer
Abstract Background and Objective Management of non-valvular atrial fibrillation (NVAF)
focuses on the use of anticoagulation to mitigate the risk of stroke. Until recently, vitamin K …
focuses on the use of anticoagulation to mitigate the risk of stroke. Until recently, vitamin K …
Cost-effectiveness of apixaban versus other direct oral anticoagulants and warfarin in the prevention of thromboembolic complications among Finnish patients with …
T Hallinen, E Soini, C Asseburg, M Linna… - ClinicoEconomics …, 2021 - Taylor & Francis
Purpose Direct oral anticoagulant (DOAC) use for the prevention of thromboembolic
complications in patients with non-valvular atrial fibrillation (AF) has increased steadily in …
complications in patients with non-valvular atrial fibrillation (AF) has increased steadily in …